Cutler Group LP Regeneron Pharmaceuticals, Inc. Call Options Transaction History

Cutler Group LP

11 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2022 Oct 25, 2022	SELL	$573.97 - $724.32 $2.01 Million - $2.54 Million	-3,500 Reduced 76.09%	1,100 $20,000
Q2 2022 Aug 04, 2022	BUY	$548.35 - $738.84 $493,515 - $664,956	900 Added 24.32%	4,600 $36,000
Q1 2022 Apr 14, 2022	BUY	$595.12 - $698.43 $2.2 Million - $2.58 Million	3,700 New	3,700 $108,000
Q1 2020 May 07, 2020	SELL	$336.18 - $494.43 $336,180 - $494,430	-1,000 Closed	0 $0
Q3 2019 Oct 28, 2019	BUY	$273.46 - $318.39 $273,460 - $318,390	1,000 New	1,000 $0
Q1 2019 May 10, 2019	SELL	$372.08 - $439.57 $5.25 Million - $6.2 Million	-14,100 Closed	0 $0
Q4 2018 Feb 05, 2019	BUY	$335.82 - $403.04 $3.69 Million - $4.43 Million	11,000 Added 354.84%	14,100 $108,000
Q2 2018 Aug 10, 2018	SELL	$284.6 - $344.99 $2.28 Million - $2.76 Million	-8,000 Reduced 72.07%	3,100 $99,000
Q1 2018 May 11, 2018	BUY	$315.82 - $393.78 $600,058 - $748,182	1,900 Added 20.65%	11,100 $176,000
Q4 2017 Jan 17, 2018	SELL	$358.63 - $469.95 $3.55 Million - $4.65 Million	-9,900 Reduced 51.83%	9,200 $191,000
Q3 2017 Oct 17, 2017	BUY	$431.38 - $504.0 $8.24 Million - $9.63 Million	19,100	19,100 $768,000

1,489

85.6M

1.54M

1.46M

Ticker REGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,190,000
Market Cap $72.2B
Description
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.